Role of alendronate and risedronate in preventing and treating osteoporosis

ABSTRACT

Alendronate and risedronate, the two oral bisphosphonates approved in the United States for preventing and treating osteoporosis, have never been compared in direct head-to-head trials, but they appear to have similar pharmacokinetics, drug interactions, adverse effect profiles, and efficacy. Alendronate, however, can be given as a once-weekly dose, whereas risedronate is not yet available in this dosage form. On the other hand, alendronate is not approved for preventing glucocorticoid-induced osteoporosis, whereas risedronate carries this indication.

KEY POINTS

Both alendronate and risedronate have been found effective in placebo-controlled trials in preventing and treating osteoporosis.

Alendronate and risedronate are generally well tolerated as long as they are taken appropriately to avoid upper gastrointestinal adverse effects.

Alendronate is slightly more expensive than risedronate; however, the once-weekly form of alendronate may enhance patient compliance and tolerability enough to offset the higher cost.

RANGE OF TREATMENTS

A variety of nonpharmacologic and pharmacologic interventions are available for preventing and treating osteoporosis. A dequate intake of calcium and vitamin D, regular exercise, smoking cessation, and limiting alcohol intake are recommended initially. Drug treatment options include estrogen replacement, raloxifene, calcitonin, calcitriol, and bisphosphonates (currently only alendronate and risedronate).

INDICATIONS FOR BISPHOSPHONATES

Risedronate is approved by the U.S. Food and Drug Administration (FDA) for preventing and treating postmenopausal osteoporosis and glucocorticoid-induced osteoporosis and for treating Paget disease of the bone.

Alendronate is also FDA-approved for treating Paget disease, for preventing and
MECHANISM OF ACTION

The mechanism of action of bisphosphonates is not fully understood. Experimental and clinical studies show that at the tissue level they inhibit bone resorption and bone turnover without directly suppressing bone formation, resulting in increased bone mass and mineralization.

Some experts suggest that bisphosphonates work by inhibiting osteoclast formation, recruitment, and activity, or by reducing the life span of osteoclasts by inducing apoptosis. Bisphosphonates may also act intracellularly, by inhibiting enzymes in the cholesterol metabolism pathway, protein-tyrosine phosphatases, or osteoclast vacuolar H⁺,K⁺-transporting adenosine triphosphatase. To date, however, we have no evidence of receptor-mediated bisphosphonate action.1

PHARMACOKINETICS: LOW ABSORPTION, NO METABOLISM, RENAL EXCRETION

The mean oral bioavailability of both alendronate and risedronate is very low and is reduced even further when taken with food, requiring that patients take these drugs at least 30 minutes before the first food, beverage (other than water), or medication of the day. Upon absorption, the bisphosphonates are distributed into the bone. We have no evidence of systemic metabolism of alendronate or risedronate and should be taken at least 30 minutes before food.
About 50% of both drugs is excreted unchanged in the urine within 24 to 72 hours.

**EFFICACY IN CLINICAL TRIALS**

To date, no clinical trial has directly compared the efficacy of alendronate and risedronate in osteoporosis treatment and prevention. Nevertheless, placebo-controlled studies of each agent individually indicate that both are effective and well tolerated in preventing postmenopausal osteoporosis (Table 1)\(^2\)-\(^4\) treating postmenopausal osteoporosis (Table 2)\(^5\)-\(^7\) and in glucocorticoid-induced osteoporosis (Table 3)\(^8\)-\(^10\).

**CONTRAINDICATIONS**

A lendronate and risedronate are contraindicated in patients with:
- Hypocalcemia
- Known hypersensitivity to any component of the product
- Inability to stand or sit upright for at least 30 minutes
- Abnormalities of the esophagus that delay esophageal emptying, such as stricture or achalasia
- Renal impairment (creatinine clearance < 30 mL/minute for risedronate or < 35 mL/minute for alendronate)
TABLE 3

Studies of alendronate and risedronate in preventing and treating glucocorticoid-induced osteoporosis

Studies with risedronate

Investigators: Cohen et al
Patients: 224 men and women ages 18 to 65 who had begun long-term prednisone therapy (7.5 mg or more per day) within the past 3 months and had not used estrogen within the past year
Treatments: Risedronate 2.5 mg or 5.0 mg once daily or placebo for 1 year
Results: Significant change in bone mineral density of the lumbar spine in both risedronate groups vs baseline (P not recorded); increased bone mineral density in the lumbar spine, femoral neck, and trochanter with risedronate 5 mg/day vs placebo (P < .001)
Adverse effects: Similar incidence in all three groups

Investigators: Reid et al
Patients: 290 men and women who had been on long-term prednisone therapy (7.5 mg or more per day) or equivalent for more than 6 months and had not used oral estrogen in the past 6 months
Treatments: Risedronate 2.5 mg or 5.0 mg once daily or placebo for 1 year
Results: Increased bone mineral density in the lumbar spine, femoral neck, and trochanter with risedronate 5 mg/day vs baseline (P < .001) and vs placebo (P < .05); incidence of vertebral fractures 5% with risedronate 5 mg/day vs 15% with placebo (P = .042)
Adverse effects: Similar incidence of upper GI events in the risedronate 5 mg/day and placebo groups

Study with alendronate

Investigators: Saag et al
Patients: 477 men and women who had been taking prednisone (7.5 mg/day or more) or an equivalent for at least 4 months and could have used estrogen
Treatments: Alendronate 5 mg once daily or 10 mg once daily or placebo for 12 months
Results: Increased bone mineral density in the lumbar spine, femoral neck, trochanter, and total body with alendronate 10 mg/day vs baseline (P < .01) and vs placebo (P < .01)
Adverse effects: No difference in serious adverse events among the three groups; a small increase in nonserious upper GI effects occurred with alendronate 10 mg/day

It is not known if alendronate and risedronate are excreted in human milk. Therefore, caution should be exercised when giving either drug to nursing women.

HOW COMMON ARE UPPER GI ADVERSE EFFECTS?

Bisphosphonate-induced upper GI adverse events are commonly cited, but the risk may be overstated and more associated with inappropriate administration. The probable mechanism for such effects is local irritation. Another possibility is that people with osteoporosis have a high incidence of upper GI complaints even without taking bisphosphonates. Indeed, in clinical trials, similar numbers of patients receiving placebo report-
ed upper GI adverse effects as did patients receiving active drug.

Miller et al.11 addressed this issue in a placebo-controlled trial of alendronate rechallenge in 172 postmenopausal women with osteoporosis, all of whom had stopped taking alendronate because of adverse upper GI events that occurred while taking the drug. After 8 weeks of rechallenge therapy, 14.5% of patients receiving alendronate and 17.3% of patients receiving placebo had stopped treatment because of upper GI complaints, including abdominal pain (29.6%), acid regurgitation (25.9%), nausea (18.5%), and gastroesophageal reflux (11.1%). The investigators suggested that upper GI complaints reported during alendronate therapy reflected a high background incidence of upper GI complaints rather than an adverse effect of alendronate.11

In another study, conducted by Adachi et al.,12 66 postmenopausal women who had previously stopped taking alendronate because of upper GI adverse effects received either risedronate 5 mg daily or placebo. After 3 months, 16.1% of patients had stopped taking placebo, compared with 11.4% of patients receiving risedronate. The investigators concluded that risedronate is as well tolerated as placebo in patients who cannot tolerate alendronate.

Are there any differences in GI adverse effects?
Lanza et al.13 assessed the effects of alendronate and risedronate on the incidence of gastric ulcers and on the esophageal and gastroduodenal mucosa in 515 postmenopausal women age 40 and older. Patients received either risedronate 5 mg daily or placebo. A latter 3 months, 16.1% of patients had stopped taking placebo, compared with 11.4% of patients receiving risedronate. The investigators concluded that risedronate is as well tolerated as placebo in patients who cannot tolerate alendronate.

However, this study had several drawbacks: it was a short-term study in healthy postmenopausal women and did not include a placebo group to determine the expected risks of gastric ulceration without intervention. The clinical relevance of the small asymptomatic ulceration observed remains unclear.14

Higher doses tested. Lanza et al.15 also assessed the potential of alendronate and risedronate to cause endoscopically observed upper GI mucosal irritation, using the highest approved doses (ie, those used in the treatment of Paget disease) and a scale for scoring mucosal erosions.

After a 28-day trial of alendronate 40 mg a day, risedronate 30 mg a day, placebo, or placebo with aspirin 650 mg four times a day for the last 7 days, patients taking risedronate and alendronate had comparable gastric and duodenal erosion scores, and these scores were significantly lower than those in patients taking aspirin.15 Esophageal erosion scores were comparable in all groups.

However, gastric ulcers (defined as larger, deeper endoscopic erosions) occurred in 3% of patients taking risedronate or alendronate, in 60% of patients taking aspirin, and in none of the patients in the placebo group. Adverse GI effects were reported by 12% in the alendronate group, 15% in the risedronate group, 35% in the aspirin group, and 22% in the placebo group.

The investigators concluded that alendronate and risedronate are generally well tolerated and that they pose a very low risk for clinically important gastric irritation, even at the highest dosages used.

### MINIMAL DRUG INTERACTIONS

Neither risedronate nor alendronate induces or inhibits the cytochrome P450 enzyme system, so interaction with other drugs is minimal. However, clinicians should note the following:

- Co-administration of calcium supplements, antacids, or oral medications with divalent cations interfere with absorption of risedronate and alendronate
- The concomitant use of aspirin and high-dose alendronate should be avoided because of an increased incidence of upper GI adverse events in clinical trials.
TABLE 4

Oral dosing recommendations for alendronate and risedronate

<table>
<thead>
<tr>
<th>INDICATION</th>
<th>ALENDRONATE</th>
<th>RISEDRONATE</th>
</tr>
</thead>
<tbody>
<tr>
<td>Postmenopausal osteoporosis</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Prevention</td>
<td>5 mg once a day OR</td>
<td>5 mg once a day OR</td>
</tr>
<tr>
<td></td>
<td>35 mg once a week</td>
<td>30 mg once a week</td>
</tr>
<tr>
<td>Treatment</td>
<td>10 mg once a day OR</td>
<td>5 mg once a day</td>
</tr>
<tr>
<td></td>
<td>70 mg once a week</td>
<td></td>
</tr>
<tr>
<td>Glucocorticoid-induced osteoporosis</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Prevention</td>
<td>5 mg once a day*</td>
<td>5 mg once a day</td>
</tr>
<tr>
<td>Treatment</td>
<td>5 mg once a day OR</td>
<td>5 mg once a day</td>
</tr>
<tr>
<td></td>
<td>10 mg once a day†</td>
<td></td>
</tr>
<tr>
<td>Paget disease</td>
<td>40 mg once a day for 6 months</td>
<td>30 mg once a day for 2 months</td>
</tr>
</tbody>
</table>

*Not FDA-approved for this indication
†If the patient is postmenopausal and is not taking estrogen

Avoid giving high-dose alendronate with aspirin

DOSAGE

Table 4 lists the dosing recommendations for risedronate and alendronate. The drugs should be given orally, at least 30 minutes before the first food or drink of the day other than water. The drugs should be swallowed while the patient is in an upright position and should be taken with a full glass of water. Patients should not lie down for 30 minutes after taking risedronate or alendronate.

Once-weekly dosing

Of note, Merck, Inc. recently received FDA approval to market two new dosage strengths of alendronate for once-weekly dosing: a 35-mg tablet for the prevention of postmenopausal osteoporosis and a 70-mg tablet for the treatment of osteoporosis.

This modified dosing schedule for treatment is based on a recent study by Schnitzer et al. comparing the efficacy and safety of oral doses of alendronate 70 mg once a week (n = 519), 35 mg twice a week (n = 369), and 10 mg once every day (n = 370). In a 1-year, double-blind, multicenter study of postmenopausal women with osteoporosis, all three regimens produced similar increases in bone mineral density at the lumbar spine, total hip, femoral neck, trochanter, and total body. All three regimens were well tolerated with no statistically significant differences in the most commonly reported upper GI events, including abdominal pain, nausea, dyspepsia, and acid regurgitation. A trend towards a lower incidence of esophageal, gastric, or duodenal adverse effects was observed with once-a-week and twice-a-week dosing vs daily dosing. The authors concluded that alendronate 70 mg once a week is a more convenient alternative to daily dosing and may enhance compliance.

Given the apparent advantages of once-weekly alendronate dosing, Woodson et al. reported a trial of risedronate 30 mg once a week for 12 months in 13 postmenopausal women with osteoporosis who did not tolerate FDA-approved therapies. Increases in bone mineral density from baseline were seen in the lumbar spine, femoral neck, and total hip, and the treatment was well tolerated. Statistical analysis was not available.

TABLE 5

Average wholesale prices for alendronate and risedronate

<table>
<thead>
<tr>
<th>PRODUCT</th>
<th>PER TABLET</th>
<th>PER MONTH</th>
</tr>
</thead>
<tbody>
<tr>
<td>Alendronate</td>
<td></td>
<td></td>
</tr>
<tr>
<td>5 mg</td>
<td>$2.12</td>
<td>$63.60*</td>
</tr>
<tr>
<td>10 mg</td>
<td>$2.12</td>
<td>$63.60*</td>
</tr>
<tr>
<td>35 mg</td>
<td>$14.82</td>
<td>$59.27†</td>
</tr>
<tr>
<td>40 mg</td>
<td>$5.30</td>
<td>$159.00‡</td>
</tr>
<tr>
<td>70 mg</td>
<td>$14.82</td>
<td>$59.27†</td>
</tr>
<tr>
<td>Risedronate</td>
<td></td>
<td></td>
</tr>
<tr>
<td>5 mg</td>
<td>$1.95</td>
<td>$58.50*</td>
</tr>
<tr>
<td>30 mg</td>
<td>$13.78</td>
<td>$413.40‡</td>
</tr>
</tbody>
</table>

*Taken once daily for osteoporosis prevention or treatment
†Taken once a week for osteoporosis prevention or treatment
‡Taken once daily for Paget disease

Prices from 2001 Drug Topics Red Book.
COST

TABLE 5 compares the average wholesale prices of alendronate and risedronate in dosages used for osteoporosis prevention and treatment. Risedronate is slightly less expensive. However, improved patient compliance and tolerability of the once-weekly form of alendronate could offset this cost difference. Further studies are necessary to directly compare adverse effects of risedronate and alendronate and to clinically evaluate the modified once-weekly dosing regimen.

REFERENCES


ADDRESS: Mandy Leonard, PharmD, Department of Pharmacy, Hb3, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195; e-mail leonarm@ccf.org.